GLP-1 RA users, compared with nonusers, were younger (mean [SD] age, 64.7 [10.7] years vs 69.0 [10.8] years; P < .001), had similar numbers of male patients (232 [49.0%] male vs 2134 [48.5%] male; P = .52), had higher body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) (mean [SD], 35.2 [7.4] vs 31.3 [7.2]; P < .001), and had more prevalent morbid obesity (87 patients [18.4%] vs 378 patients [8.6%]; P < .001) and history of lung cancers (10 patients [2.1%] vs 24 patients [0.5%]; P = .001). Here, GLP1R is linked to morbid obesity.